@article {Mallory2021.12.23.21267374, author = {Raburn Mallory and Neil Formica and Susan Pfeiffer and Bethanie Wilkinson and Alex Marcheschi and Gary Albert and Heather McFall and Michelle Robinson and Joyce S. Plested and Mingzhu Zhu and Shane Cloney-Clark and Bin Zhou and Gordon Chau and Andreana Robertson and Sonia Maciejewski and Gale Smith and Nita Patel and Gregory M. Glenn and Filip Dubovsky and for the Novavax Inc. 2019nCoV-101 Study Group}, title = {Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial}, elocation-id = {2021.12.23.21267374}, year = {2021}, doi = {10.1101/2021.12.23.21267374}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Emerging SARS-CoV-2 variants and evidence of waning vaccine efficacy present significant obstacles toward controlling the COVID-19 pandemic. Booster doses of SARS-CoV-2 vaccines may address these concerns by both amplifying and broadening the immune responses seen with initial vaccination regimens.Methods In a phase 2 study, a single booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M{\texttrademark} adjuvant (NVX-CoV2373) was administered to healthy adult participants 18 to 84 years of age approximately 6 months following their primary two-dose vaccination series. Safety and immunogenicity parameters were assessed, including assays for IgG, MN50, and hACE2 receptor binding inhibition against the ancestral SARS-CoV-2 strain and select variants (B.1.351 [Beta], B.1.1.7 [Alpha], B.1.617.2 [Delta], and B.1.1.529 [Omicron]). This trial is registered with ClinicalTrials.gov, NCT04368988.Findings An incremental increase in the incidence of solicited local and systemic reactogenicity events was observed with subsequent vaccinations. Following the booster, incidence rates of local and systemic reactions were 82.5\% (13.4\% >= Grade 3) and 76.5\% (15.3\% >= Grade 3), respectively, compared to 70.0\% (5.2\% >= Grade 3) and 52.8\% (5.6\% >= Grade 3), respectively, following the primary vaccination series. Events were primarily mild or moderate in severity and transient in nature, with a median duration of 1.0 to 2.5 days. Immune responses seen 14 days following the primary vaccination series were compared with those observed 28 days following the booster (Day 35 and Day 217, respectively). For the ancestral SARS-CoV-2 strain, serum IgG geometric mean titers (GMTs) increased \~{}4.7-fold from 43,905 ELISA units (EU) at day 35 to 204,367 EU at Day 217. Neutralization (MN50) assay GMTs showed a similar increase of \~{}4.1-fold from 1,470 at day 35 to 6,023 at Day 217. A functional hACE2 receptor binding inhibition assay analyzing activity against ancestral and variant strains of SARS-CoV-2 at Day 189 vs Day 217 found 54.4-fold (Ancestral), 21.9-fold (Alpha), 24.5-fold (Beta), 24.4-fold (Delta), and 20.1-fold (Omicron) increases in titers. An anti-rS IgG activity assay comparing the same time points across the same SARS-CoV-2 strains found titers improved 61.2-fold, 85.9-fold, 65.0-fold, 92.5-fold, and 73.5-fold, respectively.Interpretation Administration of a booster dose of NVX-CoV2373 approximately 6 months following the primary vaccination series resulted in an incremental increase in reactogenicity along with enhanced immune responses. For both the prototype strain and all variants evaluated, immune responses following the booster were notably higher than those associated with high levels of efficacy in phase 3 studies of the vaccine.Funding Novavax{\textregistered} and the Coalition for Epidemic Preparedness Innovations (CEPI{\textregistered}).Competing Interest StatementDisclosure forms provided by the authors will be available with the full text of this article upon publication.Clinical TrialNCT04368988Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04368988 Funding StatementThis study was funded by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the Alfred Hospital Human Research Ethics Committee (Melbourne, Australia) and Advarra Central Institutional Review Board (Colombia, Maryland, USA) and was performed in accordance with the International Conference on Harmonisation, Good Clinical Practice guidelines. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Availability Data Sharing Statement will be available with the full text of this article upon publication. https://clinicaltrials.gov/ct2/show/NCT04368988}, URL = {https://www.medrxiv.org/content/early/2021/12/24/2021.12.23.21267374}, eprint = {https://www.medrxiv.org/content/early/2021/12/24/2021.12.23.21267374.full.pdf}, journal = {medRxiv} }